Pulse oximeters, spirometers are used in the diagnosis of respiratory diseases. A pulse oximeter is a non-invasive medical device that is used to monitor the amount of oxygen carried by the body. A spirometer is an apparatus used to measure the volume of air inhaled and exhaled by the lungs and the rate of exhalation. The main types of pulse oximeters and spirometers are pulse oximeters and spirometers. Pulse oximeters are medical devices that measure blood oxygen saturation levels and pulse rate.Pulse oximeters and spirometers are used by a variety of end-users, including hospitals, home care settings, clinical laboratories, and industrial settings, for diagnostic and treatment monitoring. The pulse oximeters and spirometers market research report is one of a series of new reports from The Business Research Company that provides pulse oximeters and spirometers market statistics, including pulse oximeters and spirometers industry global market size, regional shares, competitors with a pulse oximeters and spirometers market share, detailed pulse oximeters and spirometers market segments, market trends and opportunities, and any further data you may need to thrive in the pulse oximeters and spirometers industry. This pulse oximeters and spirometers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pulse oximeters, spirometers market size will grow from $4.84 billion in 2022 to $4.95 billion in 2023 at a compound annual growth rate (CAGR) of 2.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global pulse oximeters, spirometers market size is expected to grow to $5.43 billion in 2027 at a CAGR of 2.3%. COVID-19 infection is a respiratory illness and therefore there is an increased demand for respiratory devices including pulse oximeters and spirometers. Oxygen therapy is a major intervention for patients with severe COVID-19 infection, and the healthcare providers need to ensure the availability of pulse oximeters and other medical oxygen systems. The market for these devices is expected to surge as they contribute to the early detection and remote monitoring of patients. Increasing incidence of Chronic Obtrusive Pulmonary Disease (COPD) globally due to an increase in aged population over 65 years of age, air pollution, and high smoking prevalence are expected to contribute to the market growth of pulse oximeters and spirometers. There will be a five-fold increased risk for COPD among the population over 65 years than the population below 40 years. Smoking and air pollution damage the lungs, which increases the risk for COPD. Indoor air pollution increases the risk of COPD by 2.65% and smoking by 90%. In 2020, globally there were 1 billion persons aged 65 years or over and it is expected to double in the forthcoming decades. Around 19% of adults smoke tobacco globally and 91% of the population reside in areas where air quality levels exceed WHO limits. Therefore, the increased prevalence of COPD among the population will increase the demand for medical equipment like pulse oximeters and spirometers for diagnosis and therapy maintenance, thus driving the market during the period. Lack of awareness among the global population about respiratory signs and symptoms has hindered the growth of the market. For instance, in according to a research study published on npj Primary care respiratory medicine, the COPD awareness among the respondents from India was less than 1%. Therefore, lack of awareness has a negative impact on the pulse oximeters and spirometers market growth. Companies in the pulse oximeters and spirometer market are increasingly focusing on developing smart and wireless oximeters and spirometers. The use of wireless technology in monitoring devices is trending nowadays, which enhances its ease of usage and data analysis. The integration of wireless technology allows the transfer of data from the device to a smartphone or a wireless device through Bluetooth or cellular connection for data processing and then to display the results. In 2020, Masimo, an American manufacturer of noninvasive patient monitoring technologies, received the first FDA clearance for a fingertip pulse oximeter that can measure respiration rate. In addition, the device will also measure oxygen saturation, pulse rate, perfusion index, and Masimo’s Pleth Variability Index (PVi). Major players in the pulse oximeter and spirometer market are Smiths Medical Inc., Koninklijke Philips N.V., Vyaire Medical, Schiller AG, General Electric Company, Masimo Corporation, Medtronic PLC., Opto Circuits Limited, Fukuda Sangyo Co. Ltd., and Hill-Rom Holdings, Inc. North America was the largest region in the pulse oximeters and spirometers market in 2022. Asia-Pacific was the second largest region in the global pulse oximeters and spirometers market. The regions covered in the global pulse oximeters and spirometers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries included in pulse oximeters and spirometers are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pulse oximeters, spirometers market consists of sales of handheld, fingertip, and other pulse oximeters, spirometers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pulse oximeters, spirometers market is segmented - 1) By Product Type: Pulse Oximeters, Spirometers 2) By End Use: Hospitals, Home Care Settings, Clinical Laboratories, Industrial settings 3) By Application: Diagnostic, Treatment Monitoring

Respiratory devices and equipment (therapeutic and diagnostic) are used to provide medication or assist a patient who is having difficulty in breathing and cannot achieve adequate oxygen levels to maintain life. Patients with respiratory disorders such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and acute respiratory distress syndrome require respiratory devices. The main types of respiratory devices and equipment are diagnostic devices, therapeutic devices, and monitoring devices. The diagnostic devices are used to diagnose respiratory-related issues. The various therapeutic devices are humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, ventilators, and others. The diagnostic devices involved are spirometer, polysomnographs, and peak flow meters and monitoring devices are pulse oximeters, capnography, and gas analyzers. These provide applications in chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea (OSA), respiratory distress syndrome (RDS), cystic fibrosis, and pneumonia. These are used by hospitals, clinics, home care settings, and ambulatory service centres. The respiratory devices and equipment (therapeutic and diagnostic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (therapeutic and diagnostic) market statistics, including respiratory devices and equipment (therapeutic and diagnostic) industry global market size, regional shares, competitors with a respiratory devices and equipment (therapeutic and diagnostic) market share, detailed respiratory devices and equipment (therapeutic and diagnostic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (therapeutic and diagnostic) industry. This respiratory devices and equipment (therapeutic and diagnostic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global respiratory devices and equipment (therapeutic and diagnostic) market size will grow from $29.09 billion in 2022 to $32.76 billion in 2023 at a compound annual growth rate (CAGR) of 12.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The respiratory devices and equipment (therapeutic and diagnostic) market size is expected to grow to $50.54 billion in 2027 at a CAGR of 11.5%. The global therapeutic respiratory devices and equipment market will be driven by the increase in diseases such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and lung cancer. Growth in the geriatric population, tobacco consumption, allergens, and air pollutants increase the prevalence of respiratory diseases, in turn driving the global therapeutic respiratory devices market. According to World Health Organisation,4.9 million people die due to tobacco consumption, and smoking causes chronic obstructive pulmonary diseases (1 million deaths annually), cardiovascular and respiratory diseases (1.7 million deaths annually), and lung cancer (0.85 million deaths annually). According to an Italian journal, COPD in the U.S. is estimated to be 10% in the population aged 75 years or over. According to Asthma UK, 5.4 million people in the UK are currently receiving treatment for asthma out of these 1.1 million are children and 4.3 million are adults. A longer duration of time taken in the approval process of the respiratory devices is restricting the respiratory devices and equipment market growth. Before a new respiratory device is introduced to the market, it takes 7.2 months for the FDA approval process, which adds to development costs to be borne by device manufacturers, thus acting as a restraint hindering the market growth. For instance, FDA reviews about 4,000 submissions every year and takes about 3 to 6 months in clearing most of them. In addition to this, to reduce incidences associated with the respiratory devices and ensure that the devices are safe and have the least adverse reactions, the Medicines and Healthcare products Regulatory Agency (MRHA), UK regulates and monitors the devices by restricting devices for use and sending field safety notice to correct the devices. These stringent approval processes and regulatory policies may impact the respiratory devices and equipment market. Companies in the respiratory devices and equipment market are increasingly investing in enhanced mechanical ventilators for efficient patient management. These mechanical ventilators use artificial intelligence to improve patient management by examining, analyzing, integrating, and incorporating data from extensive sources. These AI-enabled devices ensure consistency even in the absence of expert personnel, improve patients' treatment, limit clinical mistakes, and predict prolonged mechanical ventilation by using artificial intelligence techniques. Some of the major companies offering intelligent mechanical ventilators such as Hamilton Medical AG, Koninklijke Philips N.V., and others. In June 2021, Philips respironics issued a voluntary recall notification after discovering potential health risks related to CPAP, BiPAP and Mechanical ventilator devices. The notification also included a field safety notice for users who did not intend to send the devices for repair. Major players in the respiratory devices and equipment market are Smiths Medical, Philips Healthcare, GE Healthcare, Chart Industries, Invacare Corporation, Fisher & Paykel Healthcare Limited, ResMed, Dragerwerk AG, Medtronic PLC., Masimo corp., and CareFusion Corporation. Asia-Pacific was the largest region in respiratory devices and equipment (therapeutic and diagnostic) market in 2022. Western Europe was the second-largest region in respiratory devices and equipment (therapeutic and diagnostic) market. The regions covered in respiratory devices and equipment (therapeutic and diagnostic) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, USA, and Australia. The respiratory devices and equipment (therapeutic and diagnostic) market consists of sales of instruments such as humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, ventilators, spirometer, polysomnographs, peak flow meters, pulse oximeters, capnographs, and gas analyzers. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global respiratory devices and equipment (therapeutic and diagnostic) market is segmented - 1) By Type: Diagnostic devices, Therapeutic devices, Monitoring devices 2)By End User: Hospitals, Clinics, Homecare settings, Ambulatory service centers, 3) By Therapeutic Devices: Humidifiers, Nebulizers, Oxygen concentrators, Positive Airway Pressure (PAP) Devices, Ventilators, Other Therapeutic Devices 4) By Diagnostic Devices: Spirometer, Polysomnographs, Peak Flow Meters 5) By Monitoring Devices: Pulse oximeters, Capnographs, Gas analyzers 6) By Application: Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea (OSA), Respiratory Distress Syndrome (RDS), Cystic Fibrosis, Pneumonia

Respiratory disposables are used to interface respiratory devices with patients, such as ventilators, nebulizers, and oxygen therapy devices.  The main types of respiratory disposables are masks, tubes, inhalers, and others. A mask is a piece of cloth or other material that is personal protective equipment intended for medical purposes. These are used for disease indications such as asthma, a chronic obstructive pulmonary disorder, tuberculosis, lung cancer, and other chronic respiratory diseases. The applications involved in adult, pediatric, and neonatal. The various end-users are hospitals, clinics, ambulatory care centres, and others. The respiratory disposables market research report is one of a series of new reports from The Business Research Company that provides respiratory disposables market statistics, including respiratory disposables industry global market size, regional shares, competitors with a respiratory disposables market share, detailed respiratory disposables market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory disposables industry. This respiratory disposables market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global respiratory disposables market size will grow from $2.77 billion in 2022 to $3.07 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The respiratory disposables market size is expected to grow to $4.41 billion in 2027 at a CAGR of 9.5%. The high prevalence rate of respiratory diseases globally is driving the respiratory disposables market. Excessive smoking, exposure to toxic materials, adverse climate conditions, and air pollution are some of the main causes which are leading to a rise in respiratory diseases such as asthma, lung cancer, Chronic Obstructive Pulmonary Disease (COPD), and obstructive sleep apnea (OSA). According to a study, around 65 million people suffer from chronic obstructive pulmonary disease (COPD) and around 3 million people die every year because of this disease. It was also reported that around 334 million people suffer from asthma diseases caused by air pollution as well as tobacco smoke, toxic disposable devices. These factors are increasing the demand for the treatment of respiratory ailments, thus driving the respiratory diseases market. The respiratory disposables market is being restrained due to stringent regulatory policies. Regulatory agencies and governments across various countries are imposing stringent restrictions on product approval and launch, this is limiting the market growth. For instance, FDA banned Amphastar Pharmaceutical’s Primatene product, an albuterol CFC inhaler for asthma because ozone-depleting chlorofluorocarbon (CFC) propellants have depleted the ozone layer. The FDA rejected Amphastar’s first attempt to bring a reformulated version of Primatene mist to market. The FDA rejected another application for Primatene Mist. Which resulted in a rise in development costs and potential sales loss due to delays in product launch, thus restraining the Respiratory disposables market. Rapid advances in technology are driving innovation in respiratory disposable manufacturing. Areas of particular development are likely to be AIR gel technology, wearable technologies, and 3D printing technology. These technologies are being used in the manufacturing of respiratory disposables, resulting in higher productivity, lower costs, and higher margins. Companies in this market are increasingly focusing on AIR gel technology, in which gel is incorporated into the bag on the edges of the mask which helps to the protection of the skin and creates a bridge to minimize the irritation of the skin and for effective sealing. For example, Vyair medical prepared Veraseal 2 disposable mask, used for acute care with AIR gel technology and advantage of vented and non-vented versions. Similarly, Sleepnet prepared Mojo ventilation masks with Airgel technology. In the USA, occupational safety and health administration (OSHA) regulates all respiratory medical equipment, guidelines for which are specified in 29 CFR 1910. 134. Under OSHA, the national institute for occupational safety and health/national personal protective technology laboratory (NIOSH/ NPPTL) provides a market approval certificate and FDA approves the product for marketing. Before market approval, all the medical devices should be analyzed appropriately by performing a compatibility test within a hospital environment. They are tested on an Electrical bench and Non-clinical performance testing is also required. Moreover, proper software verification, validation, and hazard analysis must be performed. Labels on the devices are required to include the purpose of the device. In 2021, Medline a Netherland-based medical device company acquired the Hudson RCI brand of respiratory consumables from Teleflex. The acquisition helps Medline's offerings, enlarging the respiratory environment with the highly regarded Hudson RCI products and opening extra opportunities for development and help to customers. Teleflex is a US-based company global provider of medical technologies designed to develop the health and quality of people's lives. Major players in the respiratory disposables market are Fisher & Paykel, Becton Dickinson Company, Ambu A/S, Smiths Medical, Armstrong Medical, Teleflex, Philips Respironics, Besmed, ResMed, and Dynarex. Asia-Pacific was the largest region in the global respiratory disposables and equipment market in 2022. Western Europe was the second-largest region in the respiratory disposables market. The regions covered in the global respiratory disposables market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory disposables market include Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The respiratory disposables market consists of sales of instruments such as disposable resuscitators, disposable masks, nasal cannulas, tracheostomy tubes, and other consumables and accessories. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global respiratory disposables market is segmented - 1) By Type: Masks, Tubes, Inhalers, Other Types 2) By End User: Hospitals, Clinics, Ambulatory Care Centers, Other End Users 3) By Disease Indications: Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Other Chronic Respiratory Diseases 4) By Application: Adult, Pediatric & Neonatal

Respiratory monitoring devices are used to assess the patient's respiratory organs and include patches that are placed on the body to measure respiration and heart rates. The main types of respiratory monitoring devices are capnographs, gas analyzers, pulse oximeters, peak flow meters, spirometers, polysomnography, and others. Capnographs are monitoring devices that measure the concentration of carbon dioxide in exhaled air and display a numerical readout and waveform tracing. The various applications involved are chronic obstructive pulmonary disease (COPD), infectious diseases, asthma, and others that are used by end-users such as laboratories, hospitals, and home use. The respiratory monitoring devices market research report is one of a series of new reports from The Business Research Company that provides respiratory monitoring devices market statistics, including respiratory monitoring devices industry global market size, regional shares, competitors with a respiratory monitoring devices market share, detailed respiratory monitoring devices market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory monitoring devices industry. This respiratory monitoring devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global respiratory monitoring devices market size will grow from $1.32 billion in 2022 to $1.46 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global respiratory monitoring devices market size is expected to grow to $2.04 billion in 2027 at a CAGR of 8.7%. The market for respiratory monitoring devices is experiencing exponential growth due to the COVID-19 pandemic. The fact that COVID-19 is essentially a respiratory ailment has boosted the use of respiratory monitoring devices to monitor the physiological functions of the lungs during COVID-19 treatment. The rising rate of chronic respiratory diseases is expected to drive the respiratory monitoring devices market in the near future. Chronic respiratory diseases such as asthma, bronchitis, pneumonia, and others resulting from different bacterial and viral infections will boost the demand for respiratory monitoring devices. For example, in according to the National health survey 2021, 4.6% of adults agreed of ever been diagnosed with COPD, emphysema, and chronic bronchitis. Furthermore, according to the national vital statistics system, in 2020, COPD caused 152,657 deaths in the US and bronchitis caused 457 deaths in 2020. The respiratory monitoring devices such as spirometers and pulse oximeters act as essential devices to monitor vital respiratory parameters. The longer duration of time taken in the approval process of respiratory devices is restricting the growth of the respiratory monitoring devices market. Before a new respiratory device is introduced to the market, it takes 7.2 months for the FDA approval process, which adds to the development costs to be borne by device manufacturers, thus acting as a restraint to the market growth. To reduce incidences associated with respiratory devices and ensure that the devices are safe and have the least adverse reactions, regulatory authorities such as the Medicines and Healthcare products Regulatory Agency (MRHA) in the UK regulates and monitors the devices by restricting devices for use and sending field safety notices to correct the devices. These stringent approval processes and regulatory policies may impact the respiratory monitoring devices market. The companies in the market are increasingly launching smart respiratory monitoring devices to diagnose and monitor some respiratory diseases. These smart respiratory monitoring devices are Bluetooth-enabled and can be connected to smartphones to continuously monitor vital respiratory parameters. For instance, in February 2022, Aptar Pharma, a US-based manufacturer of drug delivery systems, launched HeroTracker® Sense. The new offering is a novel digital respiratory health solution that converts a standard meter dose inhaler into a smart connected healthcare device. It is useful for patients to track their MDI usage and help them stick to their prescribed doses. In June 2022, Senzime AB, a US-based manufacturer of patient monitoring systems, acquired Respiratory Motion for an initial cash payment of $19 million. The acquisition will help Senzime to expand its product portfolio in monitoring devices market and extend company’s capabilities. Respiratory motion is a US-based respiratory medical device manufacturer. Major players in the respiratory monitoring devices market are COVIDien, GE Healthcare, Philips Healthcare, ResMed, Siemens Healthcare, Merck & Co., Calando Pharmaceuticals, Quark Pharmaceuticals, Sirnaomics Inc., and Traversa Therapeutics. Asia-Pacific was the largest region in the respiratory monitoring devices market in 2022. North America was the second-largest region in the global respiratory monitoring devices market. The regions covered in the global respiratory monitoring devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory monitoring devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The respiratory monitoring devices market consists of sales of pulse oximeters, capnography, spirometers, polysomnography (PSG), peak flow meters, gas analyzers, and others that are used to monitor respiration and heart rate. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global respiratory monitoring devices market is segmented - 1) By Type: Capnographs, Gas Analyzers, Pulse Oximeters, Peak Flow Meters, Spirometers, Polysomnographs, Others Types 2) By End-User: Laboratories, Hospitals, Home Use 3) By Application: Chronic Obstructive Pulmonary Disease (COPD), Infectious Diseases, Asthma, Other Applications

Lung cancer drugs refer to anti-angiogenic drugs that are used to treat lung cancer. Lung cancer is a type of cancer that decreases the ability of the lungs to supply oxygen to the bloodstream because of the uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Based on the size of the tumor cells, lung cancer is broadly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). The main types of diseases in lung cancer drugs are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer is a type of lung cancer that grows quickly in the lungs' tissues. Small cell lung cancer has often expanded (metastasized) outside of the lungs by the time a person receives a diagnosis. This malignancy is also more likely to recur after therapy than other types of lung cancer. The different types of drugs include Gemzar, paraplatin, Taxotere, navelbine, avastin, Tarceva, Iressa, and others and are used in various sectors such as hospitals, clinics, and others. The lung cancer drugs market research report is one of a series of new reports from The Business Research Company that provides lung cancer drugs market statistics, including lung cancer drugs industry global market size, regional shares, competitors with a lung cancer drugs market share, detailed lung cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer drugs industry. This lung cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global lung cancer drugs market size will grow from $32.67 billion in 2022 to $36.53 billion in 2023 at a compound annual growth rate (CAGR) of 11.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global lung cancer drugs market size is expected to grow to $54.43 billion in 2027 at a CAGR of 10.5%. The rising prevalence rate of lung cancer is a major driver for the lung cancer market. This is mainly because an increase in the prevalence and incidence rate of lung cancer cases propels the need for drugs that enable efficient and fast treatment of the disease. It also drives the industry to maintain a strong pipeline of drugs. According to the World Health Organization report, cancer led to around 10 million deaths in 2020, out of which, lung cancer was responsible for the largest number of deaths (1.80 million deaths). The increasing use of biologics and targeted therapies is a major restraint for the lung cancer market. This is because chemical lung cancer drugs come with myriads of side effects and have a toxic effect on the body. Chemical drugs lack cell specificity, i.e., they destroy even the normal body cells along with cancer-infected cells. While biologic drugs are highly targeted and work on cancer-infected cells only. Biologic drugs are also very efficient with no side effects. Clinical studies have also found that the probability of success of biological drugs is much higher than that of conventional chemical drugs. For example, Cetuximab, Gefitinib, and Afatinib are lung cancer biologic drugs that specifically target only the muted form of tumours and do not destroy the normal body cells. Targeted drug therapy in combination with other therapies is an emerging trend in the lung cancer market. It involves the use of immunotherapy drugs combined with other therapies such as chemotherapy that help in early diagnosis, prevention, and treatment of the disease. In this regard, drug manufacturers are developing targeted drug therapies for better diagnosis and treatment of lung cancer. For example, Merck and Co. developed pembrolizumab, which is a drug that helps the immune system to detect and fight cancer cells when used in addition to chemotherapy. This combination therapy showed an improvement in lung cancer status in patients. The drug is a major product of Merck and Co. and is sold under the brand name Keytruda. The FDA's guidelines for lung cancer drugs are mentioned within the Code for Federal Regulations (CFR) title number 21 under part 312, which contains sub-parts from 'A' to 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as lung cancer. The subpart 'E' also includes guidelines for monitoring and evaluation of clinical trials of lung cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All drug manufacturers are required to abide by these regulations by the FDA. Hence, regulations such as these would also keep a check on manufacturers of lung cancer drugs. Major players in the lung cancer market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., GlaxoSmithKlin, Vertiv Co., Sanofi-Aventis, Sun Pharmaceuticals Industries and Celgene Corporation. North America was the largest region in the lung cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global lung cancer drugs market during the forecast period. The regions covered in the lung cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the lung cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The lung cancer drugs market consists of sales of bevacizumab, atezolizumab, and ramucirumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global lung cancer drugs market is segmented - 1) By Disease Type: Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC) 2) By End User: Hospitals, Clinics, Other End-Users 3) By Drugs: Gemzar, Paraplatin, Taxotere, Navelbine, Avastin, Tarceva, Iressa, Other Drugs

A pulmonologist is a doctor who specializes in lung conditions such as asthma, bronchiectasis, bronchitis, chronic obstructive pulmonary disease (COPD) and others. A pulmonologist diagnoses and treats diseases of the respiratory system. In addition to lungs, the respiratory system includes your nose, throat, trachea, airways, muscles and blood vessels. The pulmonologists market is segmented by practice into owner-solo practice, owner - group practice and partner. Solo practices are usually characterized by a small staff and typically have a limited patient base, without partners or employment affiliations with other practice organizations. They are better suited in suburban or rural areas because of the significant medical need and less competition from other medical resources. The owner-solo practice market consists of the sale of pulmonology services by entities which are managed and run by a single pulmonologist. The different disease types include chronic obstructive pulmonary disease, tuberculosis, asthma and allergy, pneumonia, lung cancer, and others. The pulmonologists market research report is one of a series of new reports from The Business Research Company that provides pulmonologists market statistics, including pulmonologists industry global market size, regional shares, competitors with a pulmonologists market share, detailed pulmonologists market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonologists industry. This pulmonologists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pulmonologists market size is expected to grow from $5.04 billion in 2022 to $5.37 billion in 2023 at a compound annual growth rate (CAGR) of 6.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The global pulmonologists market size is expected to reach $6.94 billion in 2027 at a CAGR of 6.6%. The rise in lung cancer prevalence across the globe is likely to contribute to the growth of the pulmonologists market during the forecast period. Lung cancer is a prominent type of cancer that affects the lungs. The increase in its prevalence is leading patients toward utilizing the services of pulmonologists. For example, according to data from the American Cancer Society, a non-government organization working towards aiding cancer patients, 236,740 new cases of lung cancer (117,910 in men and 118,830 in women) and about 130,180 deaths from lung cancer (68,820 in men and 61,360 in women) have been estimated in 2022. Lung cancer is by far the leading cause of cancer death, making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate cancers combined. Thereby, the cases of lung cancer are expected to drive the pulmonologist market. The major players in the pulmonologists market are focusing on using robotic bronchoscopy for early diagnosis of lung diseases and to aid in better treatment. Robotic bronchoscopy is an innovative diagnostics technology that helps in the early and accurate detection of abnormal tissues in the lungs. Pulmonologists use a handy controller to navigate a small and flexible endoscope precisely into the lung, allowing them to depict and biopsy remote parts of the lung that were otherwise inaccessible previously. This ensures the accurate detection of lung nodules and helps in the better treatment of patients. For instance, in March 2022, a team of pulmonologists in Mercy Health, a US-based hospital, started using robotic bronchoscopy for early and accurate diagnosis of lung nodules. Mercy Health’s pulmonologists used a robotic bronchoscopy called the ‘Monarch Platform’ to visualize the inside of the lungs and take a tissue sample for biopsy, allowing for more accurate and early detection of small and hard-to-reach nodules in the periphery of the lung. Robotic bronchoscopy combines advanced robotics, software, endoscopy and data science to enable these critical functions. In April 2021, Sound Physicians, a US-based physician group, acquired Southwest Pulmonary for an undisclosed amount. Through this partnership, Sound Physicians will be better prepared to improve its offering of services to high-quality critical care groups and provide top hospital systems, and exceptional services. Southwest Pulmonary is a US-based critical care, and sleep, pulmonary medicine specialist. Major players in the pulmonologists market are Mount Sinai Hospital, Cleveland Clinic, Johns Hopkins Hospital, Cedars-Sinai Medical Center, Stanford Health Care, Mayo Clinic, University of Pennsylvania, NYU Langone Hospitals, UCSF Health, UCHealth, and Olympus Corporation. North America was the largest region in the pulmonologists market in 2022. Asia Pacific is expected to be the fastest-growing region in the pulmonologists market during the forecast period. The regions covered in the pulmonologists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pulmonologists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The pulmonologists market includes revenues earned by entities by health practitioners who after completing their training and education deal with the diagnosis and treatment of disorders of the respiratory system.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pulmonologists market is segmented - 1) By Practice: Owner-Solo Practice, Owner - Group Practice, Partner 2) By Disease: Chronic Obstructive Pulmonary Disease, Tuberculosis, Asthma And Allergy, Interstitial Lung Disease, Pneumonia, Lung Cancer, Other Diseases

Respiratory devices and equipment (diagnostic) are used in the diagnosis of respiratory disorders such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. The main products of the respiratory devices and equipment (diagnostic) market are instruments and devices, assays, and reagents. The respiratory instruments and devices are used to diagnose respiratory disorders. The test type included is traditional diagnostic tests, mechanical tests, imaging tests, and molecular diagnostic tests that are used to diagnose chronic obstructive pulmonary disease, lung cancer, asthma, tuberculosis, and other diseases. These are used in hospital/clinical laboratories, physician offices, reference laboratories, and other end users. The respiratory devices and equipment (diagnostic) market research report is one of a series of new reports from The Business Research Company that provides respiratory devices and equipment (diagnostic) market statistics, including respiratory devices and equipment (diagnostic) industry global market size, regional shares, competitors with a respiratory devices and equipment (diagnostic) market share, detailed respiratory devices and equipment (diagnostic) market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory devices and equipment (diagnostic) industry. This respiratory devices and equipment (diagnostic) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global respiratory devices and equipment (diagnostic) market grew from $6.93 billion in 2022 to $7.51 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The respiratory devices and equipment (diagnostic) market is expected to grow from $10.22 billion in 2027 at a CAGR of 8.0%. The increasing prevalence of various respiratory diseases contributed to the global respiratory devices and equipment market growth by increasing the use of diagnostic devices and equipment for diagnosis and treatment. Diseases such as chronic obstructive pulmonary disease (COPD) are more prevalent in the geriatric population. COPD is a type of obstructive lung disease that results in long-term breathing problems. For instance, in June 2021, according to the world health organization data, chronic obstructive pulmonary disease (COPD) is the third disease on the list of causing death in the world. There are about 3.23 million deaths that are caused by chronic obstructive pulmonary disease (COPD).. Thus, the increased number of such cases has surged the demand for diagnostic devices and equipment, therefore driving the market’s growth. Stringent regulatory practices are expected to negatively impact the growth of diagnostic respiratory devices in the forecast period. In the USA, respiratory devices undergo a strict approval process as they come under Class III devices (that pose a significant risk to patients) as per the Food and Drug Administration (FDA) classification of medical devices. These devices require clinical evidence that supports their intended use unlike, Class I and II devices, to receive marketing approval. In countries such as China, the approval process for medical devices, especially for devices used for support or sustenance, is strict and time-consuming. Such a process has slowed the entry of medical devices into the market, thus restraining the growth. Companies in the market are increasingly investing in portable and wireless diagnostic respiratory devices. The trend is being driven by the ease of handling, cost-effectiveness, advanced features of these devices, and their suitability for use at home care organizations. Innovative technology-enabled portable respiratory devices are being launched into the market, which, unlike traditional devices, can be used for immediate diagnosis of vital signs, for example, the patients’ respiratory rate and the pulse rate. For instance, in July 2021, Tidal Medical Technologies received U.S FDA approval for the use of its InSee incentive spirometer accessory for detection of medical condition and symptoms of COVID-19 in hospital settings. In June 2020, AireHealth acquired BreathResearch for an undisclosed amount. The deal comprises the acquisition of IP, research, and patents, which include work on machine learning analytics for respiratory condition tracking. BreathResearch is a US-based company engaged in converting the airwaves of breathing into sound waves producing new respiratory analytics which improve health, fitness, and performance. Major players in the respiratory devices and equipment (diagnostic) market are ResMed. Inc., Medtronic PLC., Massimo Corporation, Fisher & Paykel Healthcare Limited, Koninklijke Philips N.V, Smiths Medical, GE Healthcare, Chart Industries, Philips Healthcare, and Becton Dickinson and Company. Asia-Pacific was the largest region in the respiratory devices and equipment (diagnostic) market in 2022. North America was the second largest region in the global respiratory devices and equipment (diagnostic) market. Eastern Europe was the smallest region in the global respiratory devices and equipment (diagnostic) market. The regions covered in the global respiratory devices and equipment (diagnostic) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment (diagnostic) market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The respiratory devices and equipment (diagnostic) market consist of sales of spirometer, polysomnographs, and peak flow meters and monitoring devices are pulse oximeters, capnography, and gas analyzers that are used for diagnosis of respiratory diseases. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global respiratory devices and equipment (diagnostic) market is segmented - 1)By Product: Instruments And Devices, Assays And Reagents 2) By Test Type: Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests 3)By Disease Type: Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Other Diseases 4) By End User: Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users

Anesthesia and respiratory devices are used in the diagnosis and treatment of respiratory diseases. This market includes respiratory devices that are used to provide medication for medical conditions such as asthma, cystic fibrosis, acute cute respiratory distress syndrome, and others. The main types of anesthesia and respiratory devices are respiratory devices and equipment (therapeutic and diagnostic), anesthesia machines, anesthesia disposables, and respiratory disposables. The respiratory disposables are designed to be discarded after excessive breathing resistance, sorbent exhaustion, physical damage, or end-of-service-life renders it unsuitable for use. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The end-users are hospitals and clinics, diagnostic laboratories, and others. The anesthesia and respiratory devices market research report is one of a series of new reports from The Business Research Company that provides anesthesia and respiratory devices market statistics, including anesthesia and respiratory devices industry global market size, regional shares, competitors with a anesthesia and respiratory devices market share, detailed anesthesia and respiratory devices market segments, market trends and opportunities, and any further data you may need to thrive in the anesthesia and respiratory devices industry. This anesthesia and respiratory devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anesthesia and respiratory devices market grew from $51.73 billion in 2022 to $57.75 billion in 2023 at a compound annual growth rate (CAGR) of 11.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The anesthesia and respiratory devices market is expected to grow to $86.16 billion in 2027 at a CAGR of 10.5%. The preference for wearable and portable medical devices is increasing and companies in the respiratory devices market are developing wearable respiratory devices to improve patient monitoring. Wearable respiratory devices are mainly worn on the torso and are used to calculate the patient’s breathing rate by measuring movements of the chest wall. They are available in various forms such as small dimensional sensors, belts, and band-aid-like devices. These devices are usually connected to speciality smartphone apps that capture and interpret data and store the data in cloud data repositories focusing on main areas of respiratory healthcare including pulse oximetry, pulmonary ventilation, air quality assessment, and activity tracking. Wearable respiratory devices reduce the workload of healthcare providers, improve the efficiencies of diagnostics, reduce costs incurred by patients in regular checkups and improve patients’ comfort. Researchers at the University of California and Khine Labs are investing in major research projects to develop comfortable wearables for patients suffering from respiratory diseases. Major companies in the anesthesia and respiratory devices market include Koninklijke Philips N.V., Resmed, Cardinal Health, Inc., 3M Company, Medtronic Inc., Boston Scientific Corporation, Fisher & Paykel Healthcare Corporation Limited, Olympus Corporation, Teleflex Inc., and Getinge Group. Asia-Pacific was the largest region in the global anesthesia and respiratory devices market in 2022. North America was the second largest region in the global anesthesia and respiratory devices market. Eastern Europe was the smallest region in the global anesthesia and respiratory devices market. The regions covered in the anesthesia and respiratory devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the anesthesia and respiratory devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The anesthesia and respiratory devices market consists of sales of instruments such as resuscitators, laryngoscopes, flexible intubation scopes, supraglottic airways, ventilator circuits, HME, and other anesthesia and respiratory instruments that are used for the diagnosis and treatment of respiratory diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anesthesia and respiratory devices market is segmented - 1) By Type: Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables